Erdosteine for nonalcoholic fatty liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1/2 interventional trial will enroll adults with NAFLD confirmed by upper abdominal ultrasound at Tanta University. Participants will receive either standard therapy alone or standard therapy plus erdosteine, with clinical and safety outcomes tracked during the treatment period. Key exclusions include significant alcohol intake, other causes of chronic liver disease, pregnancy, chronic kidney disease, and hypersensitivity to erdosteine. The trial will collect liver-related biomarkers and safety labs to provide preliminary evidence of tolerability and potential benefit.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography (US).

Exclusion Criteria:

Pregnant and/or lactating women, excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women).

Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, and autoimmune hepatitis.

Patients suffering from chronic kidney disease, hyper/hypoparathyroidism. Hypersensitivity to erdostiene.

Where it's running

• Tanta Unuversity
  Tanta, Egypt Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Peanut intake and liver health in adults with MASLD

  This study tests whether adding peanuts to daily meals for 12 weeks can improve liver markers and metabolic health in adults with MASLD.

  Recruiting Henry Ford Health System · Detroit, Michigan · NCT07646197

• Photon-counting CT and ultrasound for detecting liver fat and scarring

  This will test whether a new photon-counting CT plus ultrasound can find liver fat and scarring in adults with fatty liver or liver fibrosis, using MRI as the reference.

  Recruiting Duke University · Durham, North Carolina · NCT07495332

• Cilostazol for nonalcoholic fatty liver disease.

  This trial will test whether the medicine cilostazol can reduce liver fat and improve liver health in adults with nonalcoholic fatty liver disease.

  Recruiting Phase 1/2 Tanta University · Damietta, New Damietta · NCT07238985

• Gepaktiv compared with UDCA and Ademetionine for MAFLD with enlarged liver

  This study will try the dietary supplement Gepaktiv to see if it improves liver enzymes, liver size, and fat in adults with MAFLD and hepatomegaly compared with UDCA and ademetionine.

  Recruiting Phenomen Pharma · Tyumen, Tyumen Oblast · NCT07068191

• Combining pioglitazone and empagliflozin for treating fatty liver disease in type 2 diabetes

  This study is testing if using two diabetes medications together can help people with type 2 diabetes and fatty liver disease improve their liver health more than using either medication alone.

  Recruiting Phase 4 Seoul National University Bundang Hospital · Seongnam-si · NCT06989723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.